We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lack of Comparator Data Sinks Otezla Coverage Bid in Germany
Lack of Comparator Data Sinks Otezla Coverage Bid in Germany
Germany’s healthcare cost watchdog has recommended against paying for Celgene’s Otezla, citing a lack of evidence that the psoriasis drug offers added benefit over available therapies.